Why Novavax Could Be a Bigger COVID Vaccine Winner Than Pfizer and Moderna
Some Americans could receive COVID-19 vaccinations before the end of 2020. Two coronavirus vaccines are in a prime position to win U.S. emergency use authorization (EUA) next month -- Pfizer's (NYSE: PFE) and BioNTech's (NASDAQ: BNTX) BNT162b2 and Moderna's (NASDAQ: MRNA) mRNA-1273.
Novavax (NASDAQ: NVAX) lags behind with its experimental coronavirus vaccine candidate NVX-CoV2373. The company expects to report results from a late-stage study conducted in the U.K. in early 2021 with results from its planned U.S. late-stage study likely coming a couple of months later.
The old adage that "the early bird gets the worm" is often true. First-movers frequently achieve the greatest success. In this case, though, there's a realistic chance that Novavax will be a bigger COVID vaccine winner than Pfizer or Moderna over the long run.
Source Fool.com
